Detected ·
Typewriter Therapeutics, Inc.
$56M—
Typewriter Therapeutics raised $56M in Series A financing led by AN Venture Partners and RA Capital Management for its RNA-based jumping gene (retrotransposon) technology enabling gene insertion for cancer-targeting in vivo CAR-T cells and genetic liver diseases.
- Website
- www.typewritertx.com
- Amount
- $56 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-03 08:15:24 UTC
- Signal ID
- 7d4a01b1-9aba-4237-b7fb-c235c1e7923a
As the API returns it
{
"id": "7d4a01b1-9aba-4237-b7fb-c235c1e7923a",
"created_at": "2026-09-03T08:15:24.850968Z",
"company_name": "Typewriter Therapeutics, Inc.",
"company_website_url": "www.typewritertx.com",
"company_linkedin_url": "https://www.linkedin.com/company/typewritertx",
"event_type": "funding",
"funding_amount": 56000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Typewriter Therapeutics raised $56M in Series A financing led by AN Venture Partners and RA Capital Management for its RNA-based jumping gene (retrotransposon) technology enabling gene insertion for cancer-targeting in vivo CAR-T cells and genetic liver diseases.*"
}